Related Experiment Video
Updated: May 9, 2026
An Orthotopic Resectional Mouse Model of Pancreatic Cancer
Published on: September 24, 2020
A self antigen reopens the games in pancreatic cancer
Paola Cappello1, Francesco Novelli
1Center for Experimental Research and Medical Studies (CERMS); Città della Salute e della Scienza di Torino; University of Torino; Torino, Italy ; Department of Molecular Biotechnology and Health Sciences; University of Torino; Torino, Italy.
Abstract:
We have recently demonstrated that the administration of a plasmid coding for α-enolase can elicit robust immune responses in genetically engineered mice that spontaneously develop pancreatic cancer, resulting in a significant improvement of their survival. This approach provides a springboard for the elaboration of new forms of immunotherapy for pancreatic cancer.
Insights
We found that a plasmid encoding α-enolase triggers strong immune responses in mice with pancreatic cancer, significantly improving their survival. This offers a new avenue for pancreatic cancer immunotherapy.
Area of Science:
- Immunology
- Oncology
- Genetics
Background:
- Pancreatic cancer has a poor prognosis.
- Developing effective immunotherapies for pancreatic cancer remains a challenge.
Purpose of the Study:
- To investigate the potential of α-enolase as a target for pancreatic cancer immunotherapy.
- To evaluate the impact of α-enolase-encoding plasmid administration on immune response and survival in a mouse model of pancreatic cancer.
Main Methods:
- Utilized genetically engineered mice that spontaneously develop pancreatic cancer.
- Administered a plasmid encoding α-enolase.
- Assessed immune responses and survival rates.
Main Results:
- The administration of the α-enolase-encoding plasmid elicited robust immune responses.
- Significant improvement in survival was observed in treated mice.
- Demonstrated the potential of α-enolase as an immunotherapeutic target.
Conclusions:
- Immunotherapy targeting α-enolase shows promise for treating pancreatic cancer.
- This approach offers a novel strategy for improving survival in pancreatic cancer patients.
